Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury

Summary

In our study, 17 septic, 43 sepsis-related acute kidney injury and 24 control patients were enrolled. Blood and urine samples were collected at the intensive care unit from acutely diagnosed septic and sepsis-related acute kidney injury patients at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. Patients with malignancies needing palliative care, end-stage renal disease or kidney transplantation were excluded. Not more than one sample (venous blood, midstream spot urine) was collected from control patients. Serum and urinary actin levels were determined by quantitative Western blot. Urinary actin concentrations were expressed as µg/L, while serum actin levels were expressed as mg/L. Data were compared with laboratory and clinical parameters. Patients were categorized by the Sepsis-3 definitions and 30-day mortality data were investigated.

Conditions

• Sepsis
• Acute Kidney Injury Due to Sepsis

Interventions

OTHER

Sepsis therapy

Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.

OTHER

Sepsis-related acute kidney injury therapy

Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.

Sponsors & Collaborators

• University of Pecs

  lead OTHER

Principal Investigators

• Dániel Ragán, MD · Department of Laboratory Medicine, Medical School, University of Pécs

• Péter Kustán, MD, PhD · Department of Laboratory Medicine, Medical School, University of Pécs

• Zoltán Horváth-Szalai, MD, PhD · Department of Laboratory Medicine, Medical School, University of Pécs

• Balázs Szirmay, MD · Department of Laboratory Medicine, Medical School, University of Pécs

• Beáta Bugyi, MD, PhD · Department of Biophysics, Medical School, University of Pécs

• Andrea Ludány, MD, PhD · Department of Laboratory Medicine, Medical School, University of Pécs

• Attila Miseta, MD, DsC · Department of Laboratory Medicine, Medical School, University of Pécs

• Bálint Nagy, MD, PhD · Department of Anesthesiology and Intensive Therapy, Medical School, University of Pécs

• Diána Mühl, MD, PhD · Department of Anesthesiology and Intensive Therapy, Medical School, University of Pécs

Eligibility

Min Age

18 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-01-01

Primary Completion

2019-12-31

Completion

2019-12-31

Countries

• Hungary

Study Locations